Karyopharm Therapeutics Inc. (KPTI)

High-risk biotech with explicit going-concern language and a near-term covenant-driven liquidity wall highlighted in recent SEC filings. Despite stable revenue and very high gross margin, large ongoing losses, negative cash flow, and heavy debt relative to the equity value make the stock speculative until financing/waivers are secured.

Near-term setup is dominated by liquidity stress into the 2026-09-10 term-loan/minimum-liquidity milestone (SEC-disclosed) and a Q2 update that kept “potential default” risk in focus; last ~14d media sentiment is slightly worse than the prior 30–90d baseline (baseline polarity_score ≈ 0.00 vs recent ≈ -0.17 at primary tier). Severe red-flag cap applied due to explicit going-concern/substantial-doubt disclosure and near-term funding/covenant risk.

KPTI remains in a structurally broken downtrend. The stock is below the 20/50/200-day SMAs (2.98/6.76/7.32) and below the 9/21-day EMAs (2.09/3.35), so the primary trend is still bearish despite a one-day bounce. Momentum is only marginally improving: RSI14 is oversold at 24.41, MACD line at -1.49 is above the signal at -1.64, and the histogram is slightly positive, but MACD remains below zero and ADX14 is just 4.95, showing no strong bullish trend. Liquidity is mixed because the 20-day average dollar volume is healthy at about $6.93M, but the last 3 regular sessions averaged only about $1.40M, which fails the recent-liquidity gate and makes any rebound fragile.